Literature DB >> 30886940

Inflammation and Disease: Modelling and Modulation of the Inflammatory Response to Alleviate Critical Illness.

Judy D Day1,2, Chase Cockrell3, Rami Namas4,5, Ruben Zamora4,5, Gary An3, Yoram Vodovotz4,5.   

Abstract

Critical illness, a constellation of interrelated inflammatory and physiological derangements occurring subsequent to severe infection or injury, affects a large number of individuals in both developed and developing countries. The prototypical complex system embodied in critical illness has largely defied therapy beyond supportive care. We have focused on the utility of data-driven and mechanistic computational modelling to help address the complexity of critical illness and provide pathways towards discovering potential therapeutic options and combinations. Herein, we review recent progress in this field, with a focus on both animal and computational models of critical illness. We suggest that therapy for critical illness can be posed as a model-based dynamic control problem, and discuss novel theoretical and experimental approaches involving biohybrid devices aimed at reprogramming inflammation dynamically. Together, these advances offer the potential for Model-based Precision Medicine for critical illness.

Entities:  

Year:  2018        PMID: 30886940      PMCID: PMC6420220          DOI: 10.1016/j.coisb.2018.08.008

Source DB:  PubMed          Journal:  Curr Opin Syst Biol        ISSN: 2452-3100


  62 in total

1.  Agent-based computer simulation and sirs: building a bridge between basic science and clinical trials.

Authors:  G An
Journal:  Shock       Date:  2001-10       Impact factor: 3.454

Review 2.  Points of control in inflammation.

Authors:  Carl Nathan
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

Review 3.  Native cytokine antagonists.

Authors:  J W Larrick; S C Wright
Journal:  Baillieres Clin Haematol       Date:  1992-07

4.  Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.

Authors:  D C Angus; W T Linde-Zwirble; J Lidicker; G Clermont; J Carcillo; M R Pinsky
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

5.  In silico experiments of existing and hypothetical cytokine-directed clinical trials using agent-based modeling.

Authors:  Gary An
Journal:  Crit Care Med       Date:  2004-10       Impact factor: 7.598

6.  The acute inflammatory response in diverse shock states.

Authors:  Carson C Chow; Gilles Clermont; Rukmini Kumar; Claudio Lagoa; Zacharia Tawadrous; David Gallo; Binnie Betten; John Bartels; Gregory Constantine; Mitchell P Fink; Timothy R Billiar; Yoram Vodovotz
Journal:  Shock       Date:  2005-07       Impact factor: 3.454

Review 7.  Experimental models of gram-negative sepsis.

Authors:  S J Parker; P E Watkins
Journal:  Br J Surg       Date:  2001-01       Impact factor: 6.939

Review 8.  Complex systems analysis: a tool for shock research.

Authors:  T G Buchman; J P Cobb; A S Lapedes; T B Kepler
Journal:  Shock       Date:  2001-10       Impact factor: 3.454

9.  In silico design of clinical trials: a method coming of age.

Authors:  Gilles Clermont; John Bartels; Rukmini Kumar; Greg Constantine; Yoram Vodovotz; Carson Chow
Journal:  Crit Care Med       Date:  2004-10       Impact factor: 7.598

Review 10.  Injury research in the genomic era.

Authors:  J Perren Cobb; Grant E O'Keefe
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

View more
  2 in total

Review 1.  Quality Control Measures and Validation in Gene Association Studies: Lessons for Acute Illness.

Authors:  Maria Cohen; Ashley J Lamparello; Lukas Schimunek; Fayten El-Dehaibi; Rami A Namas; Yan Xu; A Murat Kaynar; Timothy R Billiar; Yoram Vodovotz
Journal:  Shock       Date:  2020-03       Impact factor: 3.533

2.  Divergent COVID-19 Disease Trajectories Predicted by a DAMP-Centered Immune Network Model.

Authors:  Judy D Day; Soojin Park; Benjamin L Ranard; Harinder Singh; Carson C Chow; Yoram Vodovotz
Journal:  Front Immunol       Date:  2021-10-28       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.